{"id":"evogliptin","rwe":[{"pmid":"41837731","year":"2026","title":"Cinchona-Functionalized Crown-Ether-Pinioned Calix[4]arene for a Scalable Asymmetric Organocatalytic Aza-Michael Addition Reaction.","finding":"","journal":"Organic letters","studyType":"Clinical Study"},{"pmid":"41804593","year":"2026","title":"Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.","finding":"","journal":"Pulmonology","studyType":"Clinical Study"},{"pmid":"41749418","year":"2026","title":"Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study.","finding":"","journal":"Diabetes, obesity & metabolism","studyType":"Clinical Study"},{"pmid":"41648356","year":"2026","title":"Circulating biomarkers in serum from aortic valve stenosis patients predict sex-specific drug responses in valve myofibroblasts.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41335598","year":"2025","title":"Evogliptin prevents ceramide-induced pyroptosis during calcification via modulation of NLRP3/GSDM-D mediated pathway in Vascular Smooth Muscle Cells.","finding":"","journal":"PloS one","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Dipeptidyl peptidase 4","category":"target"},{"label":"DPP4","category":"gene"},{"label":"KCNH2","category":"gene"},{"label":"A10BD22","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Dong-A ST","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Dong-A ST","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EVOGLIPTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:09:19.612861+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:09:26.544961+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EVOGLIPTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:09:27.323862+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dipeptidyl peptidase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:27.904495+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1779710/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:27.797591+00:00"}},"allNames":"suganon","offLabel":[],"synonyms":["evogliptin","suganon","DA-1229"],"timeline":[{"date":"2015-10-02","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval (Dong-A ST)"}],"approvals":[{"date":"2015-10-02","orphan":false,"company":"Dong-A ST","regulator":"Korean Food and Drug Administration (KFDA)"}],"brandName":"Suganon","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Dipeptidyl peptidase 4","targets":[{"gene":"DPP4","source":"DrugCentral","target":"Dipeptidyl peptidase 4","protein":"Dipeptidyl peptidase 4"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Suganon acts as a competitive inhibitor of Dipeptidyl peptidase 4, preventing the breakdown of incretin hormones such as GLP-1 and GIP, which in turn increases insulin secretion and decreases glucagon levels, ultimately lowering blood glucose levels."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5239","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EVOGLIPTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EVOGLIPTIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:23:41.282543","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:29.670995+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metformin","drugSlug":"metformin","fdaApproval":"1995-03-03","patentExpiry":"May 1, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rosiglitazone","drugSlug":"rosiglitazone","fdaApproval":"1999-05-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pioglitazone","drugSlug":"pioglitazone","fdaApproval":"1999-07-15","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sitagliptin","drugSlug":"sitagliptin","fdaApproval":"2006-10-16","patentExpiry":"Feb 25, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"alogliptin","drugSlug":"alogliptin","fdaApproval":"2013-01-25","patentExpiry":"Jun 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"saxagliptin","drugSlug":"saxagliptin","fdaApproval":"2009-07-31","patentExpiry":"Nov 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"linagliptin","drugSlug":"linagliptin","fdaApproval":"2011-05-02","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"evogliptin","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metformin","brandName":"metformin","genericName":"metformin","approvalYear":"1995","relationship":"same-class"},{"drugId":"rosiglitazone","brandName":"rosiglitazone","genericName":"rosiglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"pioglitazone","brandName":"pioglitazone","genericName":"pioglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"sitagliptin","brandName":"sitagliptin","genericName":"sitagliptin","approvalYear":"2006","relationship":"same-class"},{"drugId":"alogliptin","brandName":"alogliptin","genericName":"alogliptin","approvalYear":"2013","relationship":"same-class"},{"drugId":"saxagliptin","brandName":"saxagliptin","genericName":"saxagliptin","approvalYear":"2009","relationship":"same-class"},{"drugId":"linagliptin","brandName":"linagliptin","genericName":"linagliptin","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05143177","phase":"PHASE2,PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)","status":"SUSPENDED","sponsor":"REDNVIA Co., Ltd.","startDate":"2022-06-27","conditions":["Calcific Aortic Valve Disease"],"enrollment":580,"completionDate":"2026-12-30"},{"nctId":"NCT05817097","phase":"","title":"Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2023-08","conditions":["Cerebral Infarction","Infarction, Brain","Dipeptidyl-Peptidase IV Inhibitors"],"enrollment":22119,"completionDate":"2024-12-30"},{"nctId":"NCT05473806","phase":"PHASE4","title":"Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seung Up Kim","startDate":"2020-09-18","conditions":["Hepatitis B, Chronic","Fibrosis, Liver","Diabetes Mellitus, Type 2"],"enrollment":28,"completionDate":"2023-02-19"},{"nctId":"NCT04356742","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-05-26","conditions":["Type 2 Diabetes"],"enrollment":198,"completionDate":"2022-02-23"},{"nctId":"NCT04170998","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-01-02","conditions":["Type2 Diabetes"],"enrollment":283,"completionDate":"2021-12-08"},{"nctId":"NCT04195919","phase":"PHASE1","title":"The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-07-10","conditions":["Hemodialysis Patients"],"enrollment":17,"completionDate":"2021-05-24"},{"nctId":"NCT03910361","phase":"PHASE4","title":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-12","conditions":["Type2 Diabetes","Non-Alcoholic Fatty Liver Disease"],"enrollment":51,"completionDate":"2020-07-02"},{"nctId":"NCT04326166","phase":"","title":"Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-03-25","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1971,"completionDate":"2021-07-31"},{"nctId":"NCT04706637","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin","status":"UNKNOWN","sponsor":"Kyung Hee University Hospital at Gangdong","startDate":"2021-02-01","conditions":["Bone Diseases, Metabolic","Diabetes Mellitus, Type 2"],"enrollment":120,"completionDate":"2023-01-31"},{"nctId":"NCT04653779","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-12","conditions":["Diabetes Mellitus, Type 2","Renal Disease","Diabetes Mellitus","Metabolic Disease","Endocrine System Diseases"],"enrollment":54,"completionDate":"2021-07"},{"nctId":"NCT04584242","phase":"PHASE4","title":"Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-09-03","conditions":["Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes"],"enrollment":40,"completionDate":"2022-05"},{"nctId":"NCT04521452","phase":"PHASE4","title":"Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2020-09","conditions":["CAVD"],"enrollment":218,"completionDate":"2024-09"},{"nctId":"NCT03667300","phase":"PHASE2","title":"Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-03-16","conditions":["Type2 Diabetes Mellitus","Albuminuria","Renal Insufficiency"],"enrollment":209,"completionDate":"2019-05-14"},{"nctId":"NCT03766724","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-11-22","conditions":["Type2 Diabetes"],"enrollment":42,"completionDate":"2019-01-18"},{"nctId":"NCT02689362","phase":"PHASE2","title":"Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2017-08-08","conditions":["Diabetes Mellitus, Type 2"],"enrollment":146,"completionDate":"2018-08-09"},{"nctId":"NCT02974504","phase":"PHASE4","title":"Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-09","conditions":["Type2 Diabetes"],"enrollment":207,"completionDate":"2018-03"},{"nctId":"NCT02754219","phase":"PHASE1","title":"Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-09-22","conditions":["Liver Dysfunction"],"enrollment":24,"completionDate":"2018-01-19"},{"nctId":"NCT02753803","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-07-27","conditions":["Type 2 Diabetes"],"enrollment":36,"completionDate":"2017-03-10"},{"nctId":"NCT02954822","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-11-14","conditions":["Type2 Diabetes"],"enrollment":36,"completionDate":"2017-08-09"},{"nctId":"NCT02946541","phase":"PHASE3","title":"A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-07","conditions":["Type 2 Diabetes Mellitus"],"enrollment":160,"completionDate":"2015-04"},{"nctId":"NCT02949193","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":222,"completionDate":"2015-05"},{"nctId":"NCT02587975","phase":"PHASE4","title":"Effect of Evogliptin on Bone Metabolism in Human","status":"UNKNOWN","sponsor":"DongGuk University","startDate":"2016-06","conditions":["Diabetes Mellitus, Type 2","Osteoporosis"],"enrollment":20,"completionDate":"2017-03"},{"nctId":"NCT02214693","phase":"PHASE1","title":"PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-07","conditions":["Renal Impairment"],"enrollment":30,"completionDate":""},{"nctId":"NCT02375139","phase":"PHASE1","title":"A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2015-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":36,"completionDate":"2015-06"},{"nctId":"NCT02167061","phase":"PHASE1","title":"A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-07","conditions":["Type 2 Diabetes Mellitus"],"enrollment":64,"completionDate":"2014-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"09118300L7","INN_ID":"9654","UMLSCUI":"C4279601","chemblId":"CHEMBL1779710","ChEMBL_ID":"CHEMBL1779710","KEGG_DRUG":"D11023","DRUGBANK_ID":"DB12625","PDB_CHEM_ID":"8VU","PUBCHEM_CID":"25022354","MESH_SUPPLEMENTAL_RECORD_UI":"C557982"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Dong-A ST","relationship":"Original Developer"}],"publicationCount":81,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BD22","allCodes":["A10BD22","A10BH07"]},"biosimilarFilings":[],"originalDeveloper":"Dong-A ST","recentPublications":[{"date":"2026 Mar 27","pmid":"41837731","title":"Cinchona-Functionalized Crown-Ether-Pinioned Calix[4]arene for a Scalable Asymmetric Organocatalytic Aza-Michael Addition Reaction.","journal":"Organic letters"},{"date":"2026 Dec","pmid":"41804593","title":"Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.","journal":"Pulmonology"},{"date":"2026 Feb 26","pmid":"41749418","title":"Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study.","journal":"Diabetes, obesity & metabolism"},{"date":"2026 Jan 20","pmid":"41648356","title":"Circulating biomarkers in serum from aortic valve stenosis patients predict sex-specific drug responses in valve myofibroblasts.","journal":"bioRxiv : the preprint server for biology"},{"date":"2025","pmid":"41335598","title":"Evogliptin prevents ceramide-induced pyroptosis during calcification via modulation of NLRP3/GSDM-D mediated pathway in Vascular Smooth Muscle Cells.","journal":"PloS one"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Dong-A ST","companyId":"dong-a-st","modality":"Small molecule","firstApprovalDate":"2015","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"Korean Food and Drug Administration (KFDA)","status":"approved","approval_date":"2015-10-02T00:00:00.000Z","mah":"Dong-A ST","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:29.670995+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}